Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke

Hongxia Zhang, Fen Sun, Jixian Wang, Luokun Xie, Mengxiong Pan, Bei Shao, Guo Yuan Yang, Shaohua Yang, Qichuan ZhuGe, Kunlin Jin

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Stroke survivors are typically left with structural brain damage and associated functional impairment in the chronic phase of injury, for which few therapeutic options exist. We reported previously that transplantation of human embryonic stem cell (hESC)-derived neural stem cells together with Matrigel scaffolding into the brains of rats after focal ischemia reduced infarct volume and improved neurobehavioral performance. Matrigel is a gelatinous protein mixture extracted from mouse sarcoma cells, thus would not be approved for use as a scaffold clinically. In this study, we generated a gel-like scaffold from plasma that was controlled by changing the concentration of CaCl2. In vitro study confirmed that 10-20 mM CaCl2 and 10-40% plasma did not affect the viability and proliferation of human and rat bone marrow mesenchymal stem/stromal cells (BMSCs) and neural stem cells (NSCs). We transplanted plasma scaffold in combination of BMSCs into the cystic cavity after focal cerebral ischemia, and found that the atrophy volume was dramatically reduced and motor function was significantly improved in the group transplanted with scaffold/BMSCs compared with the groups treated with vehicle, scaffold or BMSCs only. Our data suggest that plasma-derived scaffold in combination of BMSCs is feasible for tissue engineering approach for the stroke treatment.

Original languageEnglish
Pages (from-to)203-214
Number of pages12
JournalAging and Disease
Volume8
Issue number2
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Mesenchymal Stromal Cells
Stroke
Injections
Neural Stem Cells
Brain
Tissue Engineering
Brain Ischemia
Sarcoma
Atrophy
Ischemia
Transplantation
Gels

Keywords

  • Aging
  • Aging-related diseases
  • Diagnosis
  • Frailty
  • Regulation
  • Senescence

Cite this

Zhang, Hongxia ; Sun, Fen ; Wang, Jixian ; Xie, Luokun ; Pan, Mengxiong ; Shao, Bei ; Yang, Guo Yuan ; Yang, Shaohua ; ZhuGe, Qichuan ; Jin, Kunlin. / Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke. In: Aging and Disease. 2017 ; Vol. 8, No. 2. pp. 203-214.
@article{033e9c20b7384b93b5ea39dc59136537,
title = "Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke",
abstract = "Stroke survivors are typically left with structural brain damage and associated functional impairment in the chronic phase of injury, for which few therapeutic options exist. We reported previously that transplantation of human embryonic stem cell (hESC)-derived neural stem cells together with Matrigel scaffolding into the brains of rats after focal ischemia reduced infarct volume and improved neurobehavioral performance. Matrigel is a gelatinous protein mixture extracted from mouse sarcoma cells, thus would not be approved for use as a scaffold clinically. In this study, we generated a gel-like scaffold from plasma that was controlled by changing the concentration of CaCl2. In vitro study confirmed that 10-20 mM CaCl2 and 10-40{\%} plasma did not affect the viability and proliferation of human and rat bone marrow mesenchymal stem/stromal cells (BMSCs) and neural stem cells (NSCs). We transplanted plasma scaffold in combination of BMSCs into the cystic cavity after focal cerebral ischemia, and found that the atrophy volume was dramatically reduced and motor function was significantly improved in the group transplanted with scaffold/BMSCs compared with the groups treated with vehicle, scaffold or BMSCs only. Our data suggest that plasma-derived scaffold in combination of BMSCs is feasible for tissue engineering approach for the stroke treatment.",
keywords = "Aging, Aging-related diseases, Diagnosis, Frailty, Regulation, Senescence",
author = "Hongxia Zhang and Fen Sun and Jixian Wang and Luokun Xie and Mengxiong Pan and Bei Shao and Yang, {Guo Yuan} and Shaohua Yang and Qichuan ZhuGe and Kunlin Jin",
year = "2017",
month = "1",
day = "1",
doi = "10.14336/AD.2017.0305",
language = "English",
volume = "8",
pages = "203--214",
journal = "Aging and Disease",
issn = "2152-5250",
publisher = "International Society on Aging and Disease",
number = "2",

}

Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke. / Zhang, Hongxia; Sun, Fen; Wang, Jixian; Xie, Luokun; Pan, Mengxiong; Shao, Bei; Yang, Guo Yuan; Yang, Shaohua; ZhuGe, Qichuan; Jin, Kunlin.

In: Aging and Disease, Vol. 8, No. 2, 01.01.2017, p. 203-214.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke

AU - Zhang, Hongxia

AU - Sun, Fen

AU - Wang, Jixian

AU - Xie, Luokun

AU - Pan, Mengxiong

AU - Shao, Bei

AU - Yang, Guo Yuan

AU - Yang, Shaohua

AU - ZhuGe, Qichuan

AU - Jin, Kunlin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Stroke survivors are typically left with structural brain damage and associated functional impairment in the chronic phase of injury, for which few therapeutic options exist. We reported previously that transplantation of human embryonic stem cell (hESC)-derived neural stem cells together with Matrigel scaffolding into the brains of rats after focal ischemia reduced infarct volume and improved neurobehavioral performance. Matrigel is a gelatinous protein mixture extracted from mouse sarcoma cells, thus would not be approved for use as a scaffold clinically. In this study, we generated a gel-like scaffold from plasma that was controlled by changing the concentration of CaCl2. In vitro study confirmed that 10-20 mM CaCl2 and 10-40% plasma did not affect the viability and proliferation of human and rat bone marrow mesenchymal stem/stromal cells (BMSCs) and neural stem cells (NSCs). We transplanted plasma scaffold in combination of BMSCs into the cystic cavity after focal cerebral ischemia, and found that the atrophy volume was dramatically reduced and motor function was significantly improved in the group transplanted with scaffold/BMSCs compared with the groups treated with vehicle, scaffold or BMSCs only. Our data suggest that plasma-derived scaffold in combination of BMSCs is feasible for tissue engineering approach for the stroke treatment.

AB - Stroke survivors are typically left with structural brain damage and associated functional impairment in the chronic phase of injury, for which few therapeutic options exist. We reported previously that transplantation of human embryonic stem cell (hESC)-derived neural stem cells together with Matrigel scaffolding into the brains of rats after focal ischemia reduced infarct volume and improved neurobehavioral performance. Matrigel is a gelatinous protein mixture extracted from mouse sarcoma cells, thus would not be approved for use as a scaffold clinically. In this study, we generated a gel-like scaffold from plasma that was controlled by changing the concentration of CaCl2. In vitro study confirmed that 10-20 mM CaCl2 and 10-40% plasma did not affect the viability and proliferation of human and rat bone marrow mesenchymal stem/stromal cells (BMSCs) and neural stem cells (NSCs). We transplanted plasma scaffold in combination of BMSCs into the cystic cavity after focal cerebral ischemia, and found that the atrophy volume was dramatically reduced and motor function was significantly improved in the group transplanted with scaffold/BMSCs compared with the groups treated with vehicle, scaffold or BMSCs only. Our data suggest that plasma-derived scaffold in combination of BMSCs is feasible for tissue engineering approach for the stroke treatment.

KW - Aging

KW - Aging-related diseases

KW - Diagnosis

KW - Frailty

KW - Regulation

KW - Senescence

UR - http://www.scopus.com/inward/record.url?scp=85018525296&partnerID=8YFLogxK

U2 - 10.14336/AD.2017.0305

DO - 10.14336/AD.2017.0305

M3 - Article

VL - 8

SP - 203

EP - 214

JO - Aging and Disease

JF - Aging and Disease

SN - 2152-5250

IS - 2

ER -